Construction of a ferroptosis scoring system and identification of LINC01572 as a novel ferroptosis suppressor in lung adenocarcinoma
暂无分享,去创建一个
Xuehai Wang | Xinyuan Zhao | Yongde Luo | Weiwei Shi | Shali Yu | Feng-Li Wang | Lingling Hong | Weiming Cui | L. Zhong
[1] Kaibin Zhu,et al. Down-regulated m6A reader FTO destabilizes PHF1 that triggers enhanced stemness capacity and tumor progression in lung adenocarcinoma , 2022, Cell Death Discovery.
[2] Wen Liu,et al. N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial Carcinoma , 2022, Oxidative medicine and cellular longevity.
[3] Linfeng Li,et al. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression , 2022, Cell Death & Disease.
[4] Wen Liu,et al. Crosstalk of Redox-Related Subtypes, Establishment of a Prognostic Model and Immune Responses in Endometrial Carcinoma , 2022, Cancers.
[5] Hongyu Zhao,et al. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma , 2022, Frontiers in Oncology.
[6] Minmin Shi,et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma , 2022, Journal of Hematology & Oncology.
[7] Xianfeng Ding,et al. Long Non-coding RNA ZFPM2-AS1: A Novel Biomarker in the Pathogenesis of Human Cancers , 2022, Molecular Biotechnology.
[8] Yiming Xu,et al. METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m6A modification , 2022, Cancer cell international.
[9] R. Geng,et al. Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC , 2022, Molecular therapy. Nucleic acids.
[10] M. Weng,et al. Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer , 2021, Journal of advanced research.
[11] Feng Zhang,et al. N6-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells , 2021, Redox biology.
[12] W. Cao,et al. RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma , 2021, Journal of experimental & clinical cancer research : CR.
[13] XiaoLi Yang,et al. Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma , 2021, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[14] Lin Chen,et al. Neutrophil extracellular traps in gastrointestinal cancer , 2021, World journal of gastroenterology.
[15] Qingguo Li,et al. A Novel Ferroptosis-Related Biomarker Signature to Predict Overall Survival of Esophageal Squamous Cell Carcinoma , 2021, Frontiers in Molecular Biosciences.
[16] Hong-yan Cheng,et al. Integrated Analysis of Cell Cycle–Related and Immunity-Related Biomarker Signatures to Improve the Prognosis Prediction of Lung Adenocarcinoma , 2021, Frontiers in Oncology.
[17] F. Mechta-Grigoriou,et al. Role of cancer‐associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer , 2021, Immunological reviews.
[18] Bingya Liu,et al. LncRNA MALAT1 promotes gastric cancer progression via inhibiting autophagic flux and inducing fibroblast activation , 2021, Cell Death & Disease.
[19] M. Doyle,et al. Interfacing Seurat with the R tidy universe , 2021, bioRxiv.
[20] X. Zhang,et al. Targeting SLC3A2 subunit of system XC- is essential for m6A reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma. , 2021, Free radical biology & medicine.
[21] Shan Mi,et al. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma , 2021, Briefings Bioinform..
[22] Sheng Wang,et al. Upregulation of CENPM facilitates lung adenocarcinoma progression via PI3K/AKT/mTOR signaling pathway , 2021, Acta biochimica et biophysica Sinica.
[23] Rusong Yang,et al. A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma , 2021, Bioengineered.
[24] Jinhui Liu,et al. Development of a novel immune-related lncRNA signature as a prognostic classifier for endometrial carcinoma , 2021, International journal of biological sciences.
[25] N. Jia,et al. LINC01572 Regulates Cisplatin Resistance in Gastric Cancer Cells by Mediating miR-497-5p , 2020, OncoTargets and therapy.
[26] W. Xue,et al. Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma , 2020, Signal Transduction and Targeted Therapy.
[27] Jingqun Tang,et al. CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c‐Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma , 2020, Thoracic cancer.
[28] S. Ju,et al. The potential role of RNA N6-methyladenosine in Cancer progression , 2020, Molecular Cancer.
[29] G. Cao,et al. Down-regulation of MBNL1-AS1 contributes to tumorigenesis of NSCLC via sponging miR-135a-5p. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[30] R. Sun,et al. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma , 2020, Medical science monitor : international medical journal of experimental and clinical research.
[31] Xiao-Li Zhu,et al. LncRNA ZFPM2‐AS1 promotes lung adenocarcinoma progression by interacting with UPF1 to destabilize ZFPM2 , 2020, Molecular oncology.
[32] A. Berghoff,et al. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7) , 2020, ESMO Open.
[33] Gang Yin,et al. Functions of N6-methyladenosine and its role in cancer , 2019, Molecular Cancer.
[34] Gang Yin,et al. Functions of N6-methyladenosine and its role in cancer , 2019, Molecular Cancer.
[35] Q. Kan,et al. The interplay between m6A RNA methylation and noncoding RNA in cancer , 2019, Journal of Hematology & Oncology.
[36] Shizhen Zhang,et al. CircRNA-ENO1 promoted glycolysis and tumor progression in lung adenocarcinoma through upregulating its host gene ENO1 , 2019, Cell Death & Disease.
[37] B. Li,et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer , 2019, Journal of Hematology & Oncology.
[38] T. Lei,et al. Screening key lncRNAs for human lung adenocarcinoma based on machine learning and weighted gene co-expression network analysis. , 2019, Cancer biomarkers : section A of Disease markers.
[39] F. Garrido. HLA Class-I Expression and Cancer Immunotherapy. , 2019, Advances in experimental medicine and biology.
[40] N. Razavian,et al. Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.
[41] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[42] Aifu Lin,et al. Membrane-lipid associated lncRNA: A new regulator in cancer signaling. , 2018, Cancer letters.
[43] M. Berger,et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.
[44] B. Zhivotovsky,et al. Cell death-based treatment of lung adenocarcinoma , 2018, Cell Death & Disease.
[45] Y. Mo,et al. LncRNA-mediated regulation of cell signaling in cancer , 2017, Oncogene.
[46] Gang Chen,et al. Clinical roles of the aberrantly expressed lncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining , 2017, Oncotarget.
[47] M. Schön,et al. Neutrophil extracellular traps: protagonists of cancer progression? , 2017, Oncogene.
[48] Yun-hui Li,et al. Integrated analysis of long non-coding RNA‑associated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma. , 2016, International journal of oncology.
[49] D-S Li,et al. Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. , 2016, European review for medical and pharmacological sciences.
[50] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[51] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[52] D. Quail,et al. Microenvironmental regulation of tumor progression and metastasis , 2014 .
[53] Angela N. Brooks,et al. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.
[54] C. Antonescu,et al. KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.
[55] Matthew D. Wilkerson,et al. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..
[56] Howard Y. Chang,et al. Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.
[57] Alberto Mantovani,et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.
[58] A. Woltman,et al. Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. , 1999, Journal of immunology.